Review Article
Designing Opioids That Deter Abuse

Robert B. Raffa,1 Joseph V. Pergolizzi Jr,2,3 Edmundo Muñiz,4 Robert Taylor Jr,5 and Jason Pergolizzi5

1 Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
2 Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
3 Department of Anesthesiology, School of Medicine, Georgetown University, Washington, DC 20057, USA
4 Kirax Corporation, Inc., Bonita Springs, FL 34134, USA
5 NEMA Research Inc., 840 111th Avenue North, Naples, FL 34108, USA

Correspondence should be addressed to Robert Taylor Jr, robert.taylor.phd@gmail.com

Received 8 May 2012; Revised 7 August 2012; Accepted 21 August 2012

Copyright © 2012 Robert B. Raffa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prescription opioid formulations designed to resist or deter abuse are an important step in reducing opioid abuse. In creating these new formulations, the paradigm of drug development target should be introduced. Biological targets relating to the nature of addiction may pose insurmountable hurdles based on our current knowledge and technology, but products that use behavioral targets seem logical and feasible. The population of opioid abusers is large and diverse so behavioral targets are more challenging than they appear at first glance. Furthermore, we need to find ways to correlate behavioral observations of drug liking to actual use and abuse patterns. This may involve revisiting some pharmacodynamic concepts in light of drug effect rather than peak concentration. In this paper we present several new opioid analgesic agents designed to resist or deter abuse using physical barriers, the inclusion of an opioid agonist or antagonist, an aversive agent, and a prodrug formulation. Further, this paper also provides insight into the challenges facing drug discovery in this field. Designing and screening for opioids intended to resist or deter abuse is an important step to meet the public health challenge of burgeoning prescription opioid abuse.

1. Introduction

A fundamental tenet and driving force of drug discovery is that there is a clear and important medical need for which we can identify a biological target. Success in drug discovery is measured insofar as this medical need is adequately addressed to the extent that our current understanding of basic science and existing technology permits. The biological target can take many forms. For example, in the case of a new angiotensin-converting enzyme (ACE) inhibitor for hypertension, there is both a clear medical need (essential hypertension) and an obvious biological target (inhibitor of the enzyme). A more complex example might be a new drug for the amelioration of symptoms of Alzheimer’s disease. The medical need for such a drug is clear, but the biological target may be only hypothetical. The justification for initiating drug discovery in this case is clear, even if the outcome is less so. Another example might be a novel insulin delivery system that provides insulin release in a manner that more closely matches blood glucose levels. In this example, the medical need is valid and the discovery target merges biological with technological principles. When it comes to designing and screening for opioids that deter abuse, the same principles should be applied, but formulators should be aware of medical needs unlike the previous examples. What are the medical needs, and, if so, what is the target?

At first, the answers might appear obvious. Prescription opioid analgesics are abused, and that abuse has negative medical and even societal consequences. It might be possible to discover opioid drugs that have less abuse liability or that are designed in a formulation that is more resistant to abuse. The first of these targets—an opioid with a lower abuse liability—currently seems less immediate. Depending on receptor and 2nd-messenger transduction processes, this approach is the more difficult path, but it is possible. For example, opioids with an agonist/antagonist mechanism such as nalbuphine and buprenorphine were originally developed with the goal of reducing abuse liability. Discovery of additional
agonist/antagonist opioids is very possible. The second target, namely, to design an opioid formulation that can deter abuse, seems quite attainable with the creative application of new technologies but still may not be enough to prevent abusers who are determined to circumvent the new barriers. Ideally, the perfect opioid would be one that delivers optimal therapeutic benefit and optimal abuse deterrence, and thus formulators should work with both goals in mind in order to satisfy both medical needs. The history of the medical use of opioids has been an interesting exercise in attempting to balance the benefits of these drugs with their associated risks. Table 1 describes events that have spurred opioid abuse as well as the events to prevent such abuse.

In this paper, we review these new technologies, but, perhaps just as importantly, we ask the question whether there is an actual medical need for these products. To answer this question, we will examine the postulated target population(s), the likely success in addressing what may be separate problems of prescription versus illicit abuse, and some of the solutions to the abuse dilemma. Thus, we attempt to apply the same criteria that would be used with a more conventional drug discovery decision.

2. Opioid Abuse

Opioid abuse can have both negative medical and societal impacts. One of the biggest concerns to date is the growing number of deaths associated with opioid overdose. From 1999 to 2008, the United States of America has seen a substantial increase in overdose related deaths [1]. The death rate due to overdose in 2008 was four times as much as in 1999, and in some states overdose-related deaths are currently outpacing the number of deaths related to motor vehicle accidents. In addition, morbidity has increased as well. Emergency department visits related to the nonmedical use of opioids has doubled between 2004 and 2008 [1]. In turn, the fear of promoting abuse by prescribing patients opioids may cause some physicians to deny a patient of needed pain therapy.

3. Target Populations

The Controlled Substances Act requires that patterns of drug abuse be evaluated when considering a drug’s abuse potential [2]. With more than 35 million Americans having used prescription opioids nonmedically [3], these patterns are diverse. Even the terminology describing these behaviors is controversial. We use the term abuse rather than misuse, inappropriate use, or nonmedical use, because the Diagnostic and Statistical Manual of Mental Disorders or DSM-IV uses “substance abuse” to describe “a maladaptive pattern of substance use manifested by recurrent and significant consequences related to the repeated use of substances” [4], and the Food and Drug Administration (FDA) uses the term “abuse” with respect to the products discussed in our paper. It should be noted that definitions related to substance-use disorders are underway for DSM-V, and definitions presented in this paper may not reflect future literature.

There exist several clinically distinguishable categories of prescription opioid abuser, including those with and without legitimate prescriptions [5]. Each subpopulation has its own motivations for taking opioids, preferred drugs and routes of administration, and specific behaviors. However, our knowledge about these populations has gaps. For example, while some sources say that most people who abuse prescription opioids obtain them from friends or relatives [3], the National Addiction Vigilance Intervention and Prevention Program (NAVIPPRO) monitoring system found that just as many abusers obtain their drugs from dealers [6]. Purchasing patterns vary by drug; hydrocodone and oxycodone are available about equally from friends and dealers, but morphine, methadone, and fentanyl are mostly obtained from dealers [6]. We have identified the following subpopulations of opioid abusers.

3.1. Opportunistic or Recreational Abuser. These individuals take prescription opioids for recreation, to pursue a high, or for experimentation. They may have limited opioid experience, often combine drugs, and rarely inject them [7].

3.2. Chronic Pain Patient. Diagnosed chronic pain patients make up less than 1% of the insured population in the United States but consume about 45% of all prescription opioids [8]. It has been estimated that up to 40% of pain patients on chronic opioid therapy display aberrant drug-related behaviors (Table 2) [9], but it is unclear to what extent aberrant drug-taking behaviors predict abuse although some experts believe they do [9, 10]. Chronic pain has been intertwined with substance abuse: 33% of individuals in a substance abuse program reported suffering from chronic pain and individuals in substance abuse treatment programs with chronic pain were significantly more likely to abuse opioids than those not reporting chronic pain (20% versus 8%, P < 0.001) [6]. The term rational abuse has been put forth to describe chronic pain patients who abuse opioids because of undertreated pain [11], but very little is known about this population.

Chronic opioid users will almost always develop physical dependence while those with drug abuse histories and other predisposing genetic or mental conditions may go on to become addicts. However, it should be made clear that physical dependence is not necessary for addiction. Physical dependence and addiction have two different definitions even though sometimes in the literature they have been used interchangeable. Physical dependence is usually defined as a physical state of adaption to a drug or substance while a person is said to be an addict when the use of the drug leads to personal harm or severe consequences. Chronic pain patients using opioids for long periods of time may first experience physical dependence which may later develop into addiction if patients have other underlying genetic predispositions, psychological conditions, or abuse history.

3.3. Persistent Drug Abuser. Persistent or habitual opioid abusers, the best studied of the subpopulations, are those whose opioid abuse is part of their lifestyle. They exhibit
Table 1: A very short modern history of opioid analgesia [19].

| Year | Event |
|------|-------|
| 1804 | Morphine isolated from opium (Germany) |
| 1827 | Morphine commercially available (Merck) |
| 1832 | Codeine isolated (France) |
| 1857 | Hypodermic needle invented |
| 1890 | First USA law regulating narcotics, a tax on opium and morphine. Narcotics can be freely bought and sold |
| 1903 | Heroin addiction is recognized as a major public health crisis in USA |
| 1905 | USA bans opium |
| 1914 | Harrison Narcotics Act requires registration of physicians, pharmacists, and others associated with narcotics prescribing and distribution |
| 1914 | Oxymorphone synthesized (Germany) |
| 1916 | Oxycodone synthesized (Germany) |
| 1923 | First US federal drug agency (US Treasury Department’s Narcotics Division) bans sale of all narcotics in USA |
| 1930 | Federal Bureau of Narcotics established in the Treasury Department |
| 1939 | Oxycodone available in USA |
| 1959 | Oxymorphone available in USA |
| 1960 | Fentanyl synthesized |
| 1964 | World Health Organization introduces concept of opioid dependence |
| 1965 | USA estimates that 750,000 citizens are addicted to heroin |
| 1967 | Talwin (pentazocine) approved for pain relief and is described as having no known potential for abuse |
| 1968 | First reports of Talwin dependence |
| 1968 | Bureau of Narcotics and Dangerous Drugs established in the Justice Department |
| 1970 | Congress passes Controlled Substances Act |
| 1973 | Drug Enforcement Administration (DEA) is set up under the Justice Department |
| 1979 | Schedule IV controlled substance act, labeling changes to include postmarketing events of addiction |
| 1982 | Talwin is reformulated to include naloxone and marketed commercially the following year |
| 1983 | The original formulation of Talwin (without naloxone) is withdrawn from market and reports of abuse decreased in next few years |
| 1999 | Veterans Health Administration launches the “Pain as the 5th Vital Sign” initiative. JCAHO and other regulatory bodies incorporate into their guidelines, which was initial start of increased opioid prescriptions |
| 2000 | Congress declares decade 2001–2010 "Decade of Pain Control and Research" |
| 2002 | Suboxone (buprenorphine/naloxone) approved |
| 2004 | Consumer lawsuit against Purdue Pharma regarding OxyContin |
| 2004 | First “around-the-clock” product approved for opioid-tolerant pain patients (Palladone, Purdue Pharma) |
| 2005 | Palladone pulled from the USA market (still available in UK) |
| 2007 | Majority of single-agent oxycodone sold in US is extended release (64%) |
| 2007 | Reports of Suboxone abuse nationally as abusers figured out how to extract buprenorphine |
| 2007 | USA consumes 82% of world’s supply of oxycodone annually |
| 2009 | Embeda (morphine with sequestered naltrexone) approved |
| 2009 | Majority of single-agent oxycodone sold in US is immediate release (54%) |
| 2010 | Safe use Initiative launched by FDA |

some unique behaviors. A study of 9 healthy prescription opioid abusers compared in a double-blind study to 9 nonopioid abusers found that abusers self-administered oxycodone during experimentally induced pain and at other times, while nonabusers only self-administered oxycodone during experimentally induced pain although the subjective effects of oxycodone were similar in both groups [12]. This suggests that subjective effects may not correlate with subsequent behaviors. Abusers were more likely to report that oxycodone made them feel sociable and talkative while nonabusers given opioids were more likely to say the drug made them feel less alert [12]. Unpleasant side effects are more likely to be reported by nonabusers than abusers [13, 14].
Table 2: Definitions.

**Aberrant drug-related behaviors**: behaviors that depart or deviate from strict adherence to the prescribed therapeutic regimen set forth by a physician. Some examples include [9, 20] (list is not exhaustive)

(i) Forging prescriptions
(ii) Stealing or borrowing drugs
(iii) Multiple episodes of loss or theft of prescription drugs
(iv) Not following prescribed dose and schedule on several occasions
(v) Using prescribed drugs before expected renewal date
(vi) Injecting or snorting opioids
(vii) Multiple unauthorized dose increases (self-escalating)
(viii) Obtaining drugs from friends, family, street, and others
(ix) Repeatedly seeking drugs from other providers or emergency rooms
(x) Concurrent use of illicit drugs (e.g., heroin, cocaine, methamphetamine, marijuana, and others)
(xi) Concurrent use of alcohol
(xii) Past history of abuse of prescription medications, and possibly street drugs
(xiii) Requests for specific drugs, especially a preference for immediate release over sustained release preparations
(xiv) Increase in anxiety, sleep disturbance, or depression
(xv) Urine drug test positive for illicit drugs or unauthorized drugs
(xvi) Doctor shopping
(xvii) Persistent oversedation or euphoria
(xviii) Appearing intoxicated
(xix) Deterioration of function at work, in the family, or socially
(xx) Decrease in physical, psychological, or social function
(xxi) Noncompliance with nonopioid components of pain treatment
(xxii) Reporting no effect from nonopioids, especially antidepressants
(xxiii) Noncompliance with nondrug components of pain treatment (psychotherapy, PT, etc.)
(xxiv) Accidents: motor vehicle, falls, and others

**Addiction**: addiction is a primary, chronic disease of brain reward, motivation, memory, and related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, social, and spiritual manifestations [21].

**Substance abuse**: a maladaptive pattern of substance use leading to clinically significant impairment or distress as manifested by one (or more) of the following, occurring within a 12-month period [22].

1. Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household).
2. Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use).
3. Recurrent substance-related legal problems (such as arrests for substance-related disorderly conduct).
4. Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (e.g., arguments with spouse about consequences of intoxication and physical fights).

**Dependence**: physical dependence is a state of adaptation that is manifested by a drug class-specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist [23].

3.3.1. **Opiate Abuser.** An opioid abuser (such as a heroin addict) changes drugs (prescription opioid) if supply is compromised. These abusers select opioids with a rapid onset of action and intense effect [7].

3.3.2. **Polydrug Abuser.** Polydrug abuser deliberately takes multiple drugs, frequently combines them, and has no clear preferences [7].

3.3.3. **Genetic Abuser.** An abuser who can become addicted to any type of drug or substance due to having the disease of addiction (Table 2). Abuse-deterrent formulations may not work well in this group and may just push these abusers to a different drug or substance [15]. Treatment in this group should focus on identifying the root causes of addiction.
3.4. Rave Abusers. The recently defined “rave” abuser is a club scene denizen seeking a long-duration high [7]. Rapid onset of action is inconsequential, and opioid abuse may be sporadic.

3.5. Those with Comorbid Mental Health Disorders or Substance Abuse. Comorbidities are common among those who abuse prescription opioids: 85% or more suffer chronic pain, 55% or more have mental disorders [8], about 40% [8] to 56% [16] have concurrent alcohol dependence, and 60% or more are nicotine dependent [17]. In addition, chemical coping has been applied to those who take prescribed or illegally obtained opioids to address an underlying mental health disorder [11]. They are normally considered the middle ground group, caught between frank addiction and health disorder [11]. They are normally considered the middle ground group, caught between frank addiction and regimen adherence [18]. They have a tendency to focus on the pharmacologic treatment of pain and disregard nonpharmacologic options for pain control (e.g., physical therapist or psychiatrist). This tendency causes patients to sometimes use medications in nonprescribed ways including self-medication by escalating the dose themselves or under times of stress use medications to cope with their problems. This group is not well studied in the literature even though they make up approximately 35% of chronic pain patients. This type of patient may not benefit greatly from abuse deterrent formulations but require psychotherapy to address the underlying mental condition or problem causing opioid misuse.

4. Opioid Attributes Liked/Disliked by Abusers

To find development targets for abuse-deterrent opioids, we need to understand what attracts abusers to particular opioids. Screening tools to help predict risk of opioid abuse have been developed [46–48] and shed light on some drug-related behaviors. Other insight comes from clinical trials enrolling opioid abusers, who may be less than truthful with investigators. In one study, nearly a quarter of respondents reported that they had used a product (fentanyl matrix transdermal system) that was not available at the time of the study [49]. Dose-effect response studies of healthy drug abusers are often generalized although their predictive value in other populations is unclear [7]. Further study is warranted. In the following sections descriptions of attributes that may contribute to drug liking are presented.

4.1. Drug Delivery Systems. In a study of drug preferences among recreational abusers (n = 42), oral tablets generally ranked higher than transdermal patches, but some transdermal patches (fentanyl) rated ahead of some tablets [50–52]. In other drug preference studies, matrix-type patches were preferred by 60% of the recreational users over gel patches [51]. Thus, delivery systems may play a part in selecting opioids for misuse.

4.2. Agent. Studies to determine the most frequently abused opioids have had mixed results. According to NAVIPPRO, the most frequently abused prescription opioids in their survey (n = 41,923 cases) are hydrocodone and oxycodone, followed by morphine and methadone [6]. Among oxycodone abusers, the use was roughly evenly split between immediate-release and extended-release formulations [6]. On the other hand, most morphine abusers preferred an extended-release formulation [6]. These results were supported by a survey of 1,818 prescription-opioid-dependent patients entering drug treatment programs, in which 75% reported oxycodone or hydrocodone as their preferred drug, with less than 5% naming fentanyl as drug of choice [17]. However, in a study of recreational drug abusers in Canada (n = 42), fentanyl was considered a highly desirable drug (oral fentanyl rated higher than the patch but both were considered more desirable than oxycodone tablets) [53]. Fentanyl is also one of the most frequently abused opioids among US healthcare professionals [53–55]. From these reports, it appears that drug preferences in specific subpopulations may emerge due to a variety of factors such as familiarity with the agent, accessibility, price, ability to conceal the drug, and reputation of the agent within that population. For example, hydrocodone and oxycodone in 2009 were the most highly prescribed opioids (84.9% of total opioids prescribed), and preference for these drugs may be due to their ease of access [56].

4.3. Product Attributes. In a survey of 491 self-reported recreational opioid users, 113 product attributes were evaluated, of which those that made an agent attractive were ease of extraction, duration of effect, and rapid onset. Withdrawal effects, injection issues (pain, slow onset), formulation deterrents (adulterants, difficulty extracting drug), slow onset of action, and unpleasant administration made an opioid unattractive [57]. When these features were tested among another group of recreational opioid users (n = 564) in terms of what drugs they had actually used, the model, though imperfect, showed some good correlations. An abuse-deterrent formulation of pentazocine and naloxone (Talwin) had the least-attractive attributes and was also rarely abused by respondents (less than 1% had ever used it).

4.4. Long-Acting versus Short-Acting Opioids. As a rule of thumb, the fastest to slowest delivery methods for onset of action are inhalation, intravenous (IV), intranasal, transmucosal, and oral [5]. Long-acting opioids have been thought to have a lower abuse potential than short-acting opioids, but a randomized, double-blind, and placebo-controlled crossover study of extended-release morphine versus hydrocodone/acetaminophen (n = 18) found that long-acting opioids do not have lower abuse potential than either short-acting opioids or placebo [58].

5. Other Opioid Attributes That May Promote Abuse

The abuse liability of a drug is generally considered the degree to which repeated consumption will occur because of its positive subjective effects, reinforcing effects or to avoid negative effects. It differs from drug liking, which is a subjective scoring system for positive and negative effects associated
with a given drug \[ 59 \]. Both abuse liability and drug liking are influenced by many factors, including drug formulation (onset of action, duration of action, and intensity of effect), cost, availability, social acceptability \[ 60 \], and even popularity among peers \[ 17 \].

Pharmacokinetic attributes of an agent, including drug absorption, bioavailability, lipophilicity, and metabolism, may affect its likeliness \[ 61 \]. Opioid attractiveness has been based in part on how rapidly peak plasma concentration (\( C_{\text{max}} \)) is reached \[ 5 \]. It may be more appropriate to think of opioids in terms of their peak effects and the time to maximal effect rather than \( T_{\text{max}} \) (time to maximum plasma concentration). In a study of IV administration of oxycodone, hydrocodone, and morphine (5, 10, and 20 mg/10/mL infused over five minutes) to 11 recreational nondependent opioid users, pharmacodynamic effects of all agents were observed within five minutes of IV administration, and physiological effects were more prolonged than subjective effects \[ 62 \]. The subjective effects of hydrocodone dissipated more rapidly than those of oxycodone or morphine although the physiological effects were similar \[ 62 \]. In preclinical studies, the time required to achieve peak plasma concentrations for IV cocaine and IV hydromorphone are similar \[ 63, 64 \], but cocaine is more rapidly transported to the brain \[ 61 \]. Thus, peak plasma and peak effect may occur at different times and for studies of opioid abuse, time to maximum effect is the more relevant variable. A study of an extended-release morphine/naltrexone capsule (ALO-01, Alpharma) reported the maximum effect or \( E_{\text{max}} \) value of the agent (both intact and crushed) versus morphine sulfate solution 120 mg based on pupillometry. The morphine solution had a significantly greater \( E_{\text{max}} \) than both intact or tampered ALO-01 (\( P < 0.001 \)) \[ 65 \]. The area under the effect (AUE) should be considered in abuse-deterrent formulations.

6. Products Designed to Resist or Deter Abuse

While abuse-deterrent or abuse-resistant labeling requires large-scale epidemiological studies, which have not yet been conducted, the theoretical value of these formulations has already been recognized by clinicians, insurance carriers, and pharmacy managers \[ 66 \]. The main approaches to the problem thus far have been a physical barrier, an agonist or antagonist that is activated when the product is altered, an aversive agent, and, most rarely, a prodrug formulation. A barrier may be either physical or pharmacological and both may provide a way to prevent consumption through alternate, unintended routes. A physical barrier can be composed of a high viscosity gel, which can prevent crushing and may be resistant to aqueous extraction. However, active ingredient may be released by mechanical erosion or enzymatic degradation. In addition, the active ingredient may be encapsulated within an insoluble coating. Pharmacological barriers may consist of a sequestered opioid antagonist or an aversive agent. Table 3 lists opioid analgesics designed to resist or deter abuse that currently are on the market or in development.

These products are new formulations of well-known agents, such as the new formulation of OxyContin, which releases from 21% to 48% less opioid when tampered (milled, manually crushed, dissolved, and boiled) than the original version \[ 29 \].

One of the first formulations intended to reduce abuse was a buprenorphine/naltrexone formulation (Suboxone). In opioid addicts, buprenorphine/naltrexone produces no euphoria \[ 67 \]. However, in opioid-naive individuals, buprenorphine/naltrexone may produce euphoria when injected \[ 68, 69 \]. This parallels findings of oral oxycodone, hydromorphone, and hydromorphone which produced unpleasant effects only in those with limited opioid experience, not in experienced users \[ 70 \]. Drugs with sequestered naltrexone or naltrexone can precipitate withdrawal and may be tampered even by patients who understand the risks \[ 71 \].

In drug discovery for abuse-deterrent opioids, creating the least undesirable product by abusers possible should be the goal. This will require drug developers to understand both how and why certain opioids are diverted by specific abuser populations.

7. Real-World Impact of Abuse-Deterrent and Abuse-Resistant Formulations

Drug liking and abuse liability are useful concepts, but we do not fully understand the strength of correlation to drug using. Even if drug liking is the correct target, we do not know, for example, how it correlates to use. For example, it would be useful to know that if we could decrease drug liking by 20%, we could reduce abuse of that drug by a given percentage.

Behavioral targets for drug development seem practical, but further study is needed, in particular of opioid abusers who are rarely included in current studies (those with a major psychiatric comorbidity, chronic pain patients, and those with another substance abuse problem) and populations of sporadic users who may go unrecognized (the chemical copper, the rave abuser). What is known about opioid abuser behavior should be correlated against actual use patterns when possible.

At the core of this problem is the nature of addiction itself, which has both neurobiological and psychological components and remains to be more clearly elucidated. Biological targets for the development of new abuse-deterrent opioids are beyond the scope of this paper but remain an important goal for future research. Our current approach to opioid pharmacodynamics requires some retooling to address opioid abuse. For example, a better understanding of \( \text{max} \) and \( T_{\text{max}} \) values may be helpful in this context.

Four main models for abuse-deterrent opioids exist currently; those with a physical barrier (which do not prevent the drug from being abused by those who take it intact, but do make it difficult to snort, smoke, or inject the drug); those with an opioid agonist or antagonist that is released when the drug is misused; those with an aversive agent (niacin); and prodrug, a compound that must undergo a chemical change within the body before becoming active. The list of
| Name | Company | Agent(s) | Description | Comment |
|------|---------|----------|-------------|---------|
| Remoxy [24] | Pain therapeutics and King Pharmaceuticals | Oxycodone extended release | Hard gelatin capsule containing viscous liquid | ORADUR technology (extended-release formulation) |
| Acuracet [25] | Acura | Oxycodone immediate release and acetaminophen | Impediments to snorting and injection (not further described) | |
| Vycavert [26] | Collegium pharmaceutical | Hydrocodone immediate release and acetaminophen | Impediments to snorting and injection (not further described) | |
| COL-003 [27] | Collegium pharmaceutical | Oxycodone sustained release | Multiparticulate matrix with particles in waxy excipient base | |
| COL-172 [27] | Collegium pharmaceutical | Oxycodone sustained release | Multiparticulate matrix with particles in waxy excipient base | |
| ReXista [28] | Intellipharmaceutics | Oxycodone sustained release | Not described | |
| OxyContin [29] | Purdue | Oxycodone controlled release | Resists crushing and dissolving | |
| TQ-1015 [30] | TheraQuest Biosciences | Tramadol extended release | Transforms into viscous substance when hydrated | |
| TQ1020 [32] | Labopharm/Paladin | Levorphanol extended release | Not stated | |
| DDS-08B [33] | Neuromed/Covidien | Oxycodone/APAP extended release | Extended release even if tablet is tampered with | |
| Exalgo [34] | Neuromed/Covidien | Hydromorphone extended release | Osmotic delivery system (OROS push-pull technology) New formulation | |
| Not named [35] | Pisgah Labs | Hydrocodone | Insoluble at pH ranges in mucosal membranes | |
| ADPREM [36, 37] | Egalet (Denmark) | Morphine | Erodible matrix covered by water-impermeable nonerodible shell | |
| Egalet hydrocodone [36] | Egalet (Denmark) | Hydrocodone | Hard matrix | |
| Embeda [38] | King Pharmaceuticals | Morphine/naltrexone | Pellets of morphine surrounding a hard core of sequestered naltrexone | Naltrexone pellets are 1.0 to 1.7 mm diameter |
| ALO-01 [39] | Alpharma | Morphine extended release with naltrexone | Sequestered naltrexone | |
| Oxytrex [40] | Albert Einstein College of Medicine | Oxycodone and ultra-low-dose naltrexone | Ultra-low-dose naltrexone | |
| OxyNal or ELI-216 [40] | Elite Pharmaceuticals | Oxycodone-controlled release with naltrexone pellets | Pellets release naltrexone only when crushed | |
| Talwin [41] | Sanofi-Aventis | Pentazocine and naloxone | Naloxone | Naloxone released if drug administered parenterally |
| Suboxone Film [42] | Reckitt Benckiser | Buprenorphine/naloxone | Naloxone | |
| Acurox with niacin [43] | Acura Pharmaceuticals and King Pharmaceuticals | Oxycodone immediate release 5 and 7.5 mg | Niacin; tablets contain a gel-forming ingredient | |
| NRP 290 [44, 45] | New River Pharmaceuticals | Conditional bioreversible derivative of hydrocodone | Lysine-modified prodrug | NRP 369 is backup for NRP 290 |
products in Table 3 is complete to the extent of our knowledge. As these products come into more widespread use, actual experience with the drugs will help shape the next generation of products.

Of course, the authors do not believe that abuse-deterrent opioids will end opioid abuse. The goals of abuse-deterrent opioid formulations are limited and specific to the agents studied. It may be that abuse-deterrent formulations will simply lead to new drug choices by abusers. Surprisingly, there appears to be some degree of “brand loyalty” among recreational abusers in that some products are so well liked that online forums (Opiophile.com, Topix.com opioid forum, Prescriptiondrug-info.com, etc.) discuss how to circumvent tamper-proof mechanisms. That actual real-world effect of these drugs remains to be seen.

8. Conclusion

Prescription opioid misuse and abuse is a serious and pervasive public health crisis. Creating abuse-deterrent opioid formulations may be an important step in combating opioid abuse. Creating products based on behavior targets seems feasible, if complex, because of the diversity of populations who abuse opioids. Pharmacodynamic concepts are helpful in the creation of such new formulations but may need to be refined to be more specific to abuser populations. For example, drug liking can be measured, but it is unclear how to correlate this directly to actual drug abuse. Time to maximum effect may be a more useful metric for abuse-deterrent products than maximum serum concentration. Several abuse-deterrent opioid formulations are on the market or in development. Real-world experience with these formulations and ongoing efforts to better understand metrics associated with abuse liability (drug craving and drug liking) are needed to help guide and inform further efforts in creating abuse-deterrent opioid products.

Disclosures

J. V. Pergolizzi is a consultant for Grünenthal, Purdue Pharma, Endo Pharmaceuticals, and Collegium Pharmaceutical. R. B. Raffa is a speaker, consultant, and basic science investigator for several pharmaceutical companies involved in analgesics research but receives no royalty (cash or otherwise) from the sale of any product.

Conflict of Interests

R. Taylor and E. Muniz have no conflict of interests to report.

References

[1] “Emergency department visits involving nonmedical use of selected prescription drugs—United States, 2004–2008,” Morbidity and Mortality Weekly Report, vol. 59, no. 23, pp. 705–709, 2010.

[2] Anon, “Controlled substances act, part B. Authority and criteria for classification of substances,” in 21 United States Code, D. E. Administration, Ed., Office of Diversion Control, Washington, DC, USA, 2004.

[3] SAMHSA, Results from the 2009 National Survey on Drug Use and Health: Detailed tables, http://oas.samhsa.gov/NSDUH/2k9NSDUH/tabs/Sect1peTabs54to58.pdf, 2010.

[4] APA, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 2000.

[5] S. H. Budman, J. M. Grimes Serrano, and S. F. Butler, “Can abuse deterrent formulations make a difference? Expectation and speculation,” Harm Reduction Journal, vol. 6, pp. 8–15, 2009.

[6] S. F. Butler, S. H. Budman, A. Licari et al., “National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 12, pp. 1142–1154, 2008.

[7] N. F. Katz, E. H. Adams, H. Chilcoat et al., “Challenges in the development of prescription opioid abuse-deterrent formulations,” Clinical Journal of Pain, vol. 23, no. 8, pp. 648–660, 2007.

[8] T. J. Cicero, G. Wong, Y. Tian, M. Lymskye, A. Todorov, and K. Isenberg, “Co-morbidity and utilization of medical services by pain patients receiving opioid medications: Data from an insurance claims database,” Pain, vol. 144, no. 1-2, pp. 20–27, 2009.

[9] S. D. Passik, K. L. Kirsh, K. B. Donaghy, and R. K. Portenoy, “Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse,” Clinical Journal of Pain, vol. 22, no. 2, pp. 173–181, 2006.

[10] R. K. Portenoy, “Opioid therapy for chronic nonmalignant pain: a review of the critical issues,” Journal of Pain and Symptom Management, vol. 11, no. 4, pp. 203–217, 1996.

[11] L. R. Webster and R. M. Webster, “Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool,” Pain Medicine, vol. 6, no. 6, pp. 432–442, 2005.

[12] S. D. Comer, M. A. Sullivan, S. K. Vosburg, W. J. Kowalczyk, and J. Houser, “Abuse liability of oxycodone as a function of pain and drug use history,” Drug and Alcohol Dependence, vol. 109, no. 1–3, pp. 130–138, 2010.

[13] J. P. Zacny, S. Gutierrez, and S. A. Bobbolan, “Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users,” Drug and Alcohol Dependence, vol. 78, no. 3, pp. 243–252, 2005.

[14] J. P. Zacny and S. Gutierrez, “Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers,” Psychopharmacology, vol. 170, no. 3, pp. 242–254, 2003.

[15] T. J. Cicero, M. S. Ellis, and H. L. Surratt, “Effect of abuse-deterrent formulation of oxycodone,” New England Journal of Medicine, vol. 367, no. 2, pp. 187–189, 2012.

[16] N. Katz, Clinical Studies of Abuse Deterrent Opioid Analgesics: Definitions, Current Approaches, and Critical Issues, IMMPACT-X, Arlington, VA, USA, 2009.

[17] T. J. Cicero, M. S. Ellis, A. Paradis, and Z. Orthal, “Determinants of fentanyl and other potent μ opioid agonist misuse in opioid-dependent individuals,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 10, pp. 1057–1063, 2010.

[18] S. Passik and K. Kirsh, “Chemical coping: the clinical middle ground,” in Pain and Chemical Dependency, H. S. Smith and
S. Passik, Eds., Oxford University Press, New York, NY, USA, 2008.

[19] Booth, A Brief History of Opium, 2010.

[20] American College of Physicians, Aberrant Drug-Related Behaviors, http://www.acponline.org/about-acp/chapters/az/aberrant.pdf, 2012.

[21] American Society of Addiction Medicine, Public Policy Statement: Definition of Addiction, http://www.asam.org/for-the-public/definition-of-addiction, 2011.

[22] A. P. Association, Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision), American Psychiatric Publishing, Arlington, VA, USA, 4th edition, 2000.

[23] American Academy of Pain Medicine, The American Pain Society, and The American Society of Addiction Medicine, “Definitions related to the use of opioids for the treatment of pain,” Wisconsin Medical Journal, vol. 100, no. 5, pp. 28–29, 2001.

[24] M. Zamloot, W. Chao, L. L. Kang, J. Ross, and R. Fu, “Remoxy ®: A novel formulation of extended-release oxycodone developed using the ORADUR ® technology,” International Journal of Applied Research in Veterinary Medicine, vol. 10, no. 3, pp. 88–96, 2010.

[25] Acura, Acuracet, http://acurapharm.com/products/acuracet-tablets/, 2010.

[26] Acura, Vycavert, http://acurapharm.com/products/vycavert-tablets/, 2010.

[27] Pharmaceutical, C. Central Nervous System, Product Pipeline, http://www.collegiumpharma.com/products/cms.html, 2010.

[28] Intellipharmaceutics, Resista Oxycode, http://www.intellipharmaceutics.com/oxycodeone.cfm, 2010.

[29] J. Haddox, J. E. Henningfield, and R. Mannion, A new formulation of oxyContin (oxycodone HCL controlled-release) tablets, http://www.fda.gov/ohrms/Docket/ac08/slides/2008-3566s1-05-purdue.pdf, 2008.

[30] TheraQuest, TheraQuest Bioscience, Inc’s IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA, BioSpace, http://www.biospace.com/newsstory.aspx?NewsEntryId=117355, 2008.

[31] Anon, US orphan status for TheraQuest’s TQ-1017, The Pharma Letter, http://www.thepharmaletter.com/file/41950/us-orphan-status-for-theraquests-tq-1017.html, 2005.

[32] TheraQuest, TheraQuest Biosciences, Inc., unveils new pain management product pipeline, Press release, http://www.biospace.com/newsstory.aspx?NewsEntryId=185046, 2010.

[33] Labopharm, DDS-08B: Abuse/misuse-deterrent formulation of twice-daily oxycodone-acetaminophen, http://www.labopharm.com/default.aspx?id=217, 2010.

[34] N. Pharmaceuticals, EXALGO (hydromorphone HCl) Extended-Release Tablets CII, Joint Meeting Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee 2009 September 23, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM183035.pdf, 2009.

[35] Pisgah, Therapeutic discovery grant accelerates investigational new drug with abuse deterrent technology, Press release, http://www.pisgahlabs.com/General/PressRelease.aspx, 2010.

[36] Egalet, Technology overview, http://www.egalet.com/index.jsp?area=7, 2009.

[37] D. Ridgway, M. Sopata, A. Burneckis, L. Jespersen, and C. Andersen, “Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study,” Journal of Pain and Symptom Management, vol. 39, no. 4, pp. 712–720, 2010.

[38] Anon, Embeda Package Insert, King Pharmaceuticals, Inc, Bristol, Tenn, USA, 2009.

[39] Anon, Phase 2 results of investigational abuse-deterrent opioid ALO-01 presented by Alpharma, Medical News Today, http://www.medicalnewstoday.com/printfriendlynews.php?newsid=85689, 2007.

[40] L. Webster, “Update on abuse-resistant and abuse-deterrent approaches to opioid formulations,” Pain Medicine, vol. 10, no. 2, pp. S124–S133, 2009.

[41] Anon, Talwin Nx CIV Package Insert, http://products.sanoff-aventis.us/talwin_nx/talwin Nx.pdf, 2008.

[42] Anon, Treatment with Suboxone Film: understanding the benefits, http://www.suboxone.com/patients/about-suboxone/Default.aspx, 2010.

[43] Acura, Acura Tablets, http://acurapharm.com/products/acuractablets-without-niacin-tablets/, 2010.

[44] Anon, Guidance for Industry: Assessment of Abuse Potential of Drugs, U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Silver Spring, Md, USA, 2010.

[45] L. Gershell and J. J. Goater, “Making gains in pain,” Nature Reviews Drug Discovery, vol. 5, no. 11, pp. 889–890, 2006.

[46] H. Akbik, S. F. Butler, S. H. Budman, K. Fernandez, N. P. Katz, and R. N. Jamison, “Validation and clinical application of the screener and opioid assessment for patients with pain (SOAPP),” Journal of Pain and Symptom Management, vol. 32, no. 3, pp. 287–293, 2006.

[47] S. F. Butler, K. Fernandez, C. Benoît, S. H. Budman, and R. N. Jamison, “Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R),” Journal of Pain, vol. 9, no. 4, pp. 360–372, 2008.

[48] S. F. Butler, S. H. Budman, K. Fernandez, and R. N. Jamison, “Validation of a screener and opioid assessment measure for patients with chronic pain,” Pain, vol. 112, no. 1-2, pp. 65–75, 2004.

[49] S. F. Butler, C. Benoît, S. H. Budman et al., “Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers,” Harm Reduction Journal, vol. 3, 2006.

[50] F. Berrendero, B. L. Kieffer, and R. Maldonado, “Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knockout mice,” Journal of Neuroscience, vol. 22, no. 24, pp. 10935–10940, 2002.

[51] E. M. Sellers, R. Schuller, M. K. Romach, and G. L. Horbay, “Relative abuse potential of opioid formulations in Canada: a structured field study,” Journal of Opioid Management, vol. 2, no. 4, pp. 219–227, 2006.

[52] B. L. Kieffer, “Opioids: first lessons from knockout mice,” Trends in Pharmacological Sciences, vol. 20, no. 1, pp. 19–26, 1999.

[53] M. Rosenberg, “Drug abuse in oral and maxillofacial training programs,” Journal of Oral and Maxillofacial Surgery, vol. 44, no. 6, pp. 458–462, 1986.

[54] C. F. Ward, G. C. Ward, and L. J. Saidman, “Drug abuse in anesthesia training programs. A survey: 1970 through 1980,” Journal of the American Medical Association, vol. 250, no. 7, pp. 922–925, 1983.

[55] H. D. Silsby, D. J. Kruzhich, and M. R. Hawkins, “Fentanyl citrate abuse among health care professionals,” Military Medicine, vol. 149, no. 4, pp. 227–228, 1984.
[56] N. D. Volkow, T. A. McLellan, J. H. Cotto, M. Karithanom, and S. R. B. Weiss, “Characteristics of opioid prescriptions in 2009,” Journal of the American Medical Association, vol. 305, no. 13, pp. 1299–1301, 2011.

[57] S. F. Butler, K. C. Fernandez, A. Chang et al., “Measuring attractiveness for abuse of prescription opioids,” Pain Medicine, vol. 11, no. 1, pp. 67–80, 2010.

[58] B. L. Wilsey, S. Fishman, C. S. Li, J. Storment, and A. Albanese, “Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial,” Pharmacology Biochemistry and Behavior, vol. 94, no. 1, pp. 98–107, 2009.

[59] E. C. O’Connor and A. N. Mead, “Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans,” Pharmacology Biochemistry and Behavior, vol. 96, no. 3, pp. 279–286, 2010.

[60] J. L. Katz and S. R. Goldberg, “Preclinical assessment of abuse liability of drugs,” Agents and Actions, vol. 23, no. 1-2, pp. 18–26, 1988.

[61] M. E. Abreu, G. E. Bigelow, L. Fleisher, and S. L. Walsh, “Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans,” Psychopharmacology, vol. 154, no. 1, pp. 76–84, 2001.

[62] W. W. Stoops, K. W. Hatton, M. R. Lofwall, P. A. Nuzzo, and S. L. Walsh, “Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies,” Psychopharmacology, vol. 212, no. 2, pp. 193–203, 2010.

[63] S. M. Evans, E. J. Cone, and J. E. Henningfield, “Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects,” Journal of Pharmacology and Experimental Therapeutics, vol. 279, no. 3, pp. 1345–1356, 1996.

[64] H. F. Hill, B. A. Coda, A. Tanaka, and R. Schaffer, “Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects,” Anesthesia and Analgesia, vol. 72, no. 3, pp. 330–336, 1991.

[65] J. Stauffer, B. Setnik, M. Sokolowska, M. Romach, F. Johnson, and E. Sellers, “Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study,” Clinical Drug Investigation, vol. 29, no. 12, pp. 777–790, 2009.

[66] J. P. Schneider, M. Matthews, and R. N. Jamison, “Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?” CNS Drugs, vol. 24, no. 10, pp. 805–810, 2010.

[67] K. B. Stoller, G. E. Bigelow, S. L. Walsh, and E. C. Strain, “Effects of buprenorphine/naloxone in opioid-dependent humans,” Psychopharmacology, vol. 154, no. 3, pp. 230–242, 2001.

[68] E. C. Strain, K. Stoller, S. L. Walsh, and G. E. Bigelow, “Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers,” Psychopharmacology, vol. 148, no. 4, pp. 374–383, 2000.

[69] K. Mammen and J. Bell, “The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence,” Expert Opinion on Pharmacotherapy, vol. 10, no. 15, pp. 2537–2544, 2009.

[70] S. L. Walsh, P. A. Nuzzo, M. R. Lofwall, and J. R. Holtman, “The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers,” Drug and Alcohol Dependence, vol. 98, no. 3, pp. 191–202, 2008.

[71] X. Ruan, T. Chen, J. Gudin, J. P. Couch, and S. Chiravuri, “Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature,” Journal of Opioid Management, vol. 6, no. 4, pp. 300–303, 2010.